These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27981812)

  • 21. Inhibition of fatty acid amide hydrolase by BIA 10-2474 in rat brain.
    Tong J; Mizrahi R; Houle S; Kish SJ; Boileau I; Nobrega J; Rusjan PM; Wilson AA
    J Cereb Blood Flow Metab; 2017 Nov; 37(11):3635-3639. PubMed ID: 27650910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. INTRODUCTION: Public Sector and Non-Profit Contributions to Drug Development - Historical Scope, Opportunities, and Challenges.
    Sarpatwari A; Kesselheim AS
    J Law Med Ethics; 2021; 49(1):6-9. PubMed ID: 33966663
    [No Abstract]   [Full Text] [Related]  

  • 23. Reforming the Orphan Drug Act for the 21st Century.
    Sarpatwari A; Kesselheim AS
    N Engl J Med; 2019 Jul; 381(2):106-108. PubMed ID: 31291512
    [No Abstract]   [Full Text] [Related]  

  • 24. Bullying biosimilars: cheaper drugs stymied in USA.
    The Lancet Gastroenterology Hepatology
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):371. PubMed ID: 29739669
    [No Abstract]   [Full Text] [Related]  

  • 25. Biotechnology company's shares dive 67% after drug failure.
    Dobson R
    BMJ; 2000 Oct; 321(7268):1039. PubMed ID: 11053161
    [No Abstract]   [Full Text] [Related]  

  • 26. TGN-1412 and BIA-2474 Trials with Tragic End: Lessons Learnt To Make Clinical Trials Safer.
    Kaur RJ; Singh S; Sidhu P; Sharma PK
    Rev Recent Clin Trials; 2018; 13(4):252-256. PubMed ID: 29779485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Global Portrait of Protein Targets of Metabolites of the Neurotoxic Compound BIA 10-2474.
    Huang Z; Ogasawara D; Seneviratne UI; Cognetta AB; Am Ende CW; Nason DM; Lapham K; Litchfield J; Johnson DS; Cravatt BF
    ACS Chem Biol; 2019 Feb; 14(2):192-197. PubMed ID: 30702848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physiologically Based Pharmacokinetic Modeling in Pregnancy: A Systematic Review of Published Models.
    Dallmann A; Pfister M; van den Anker J; Eissing T
    Clin Pharmacol Ther; 2018 Dec; 104(6):1110-1124. PubMed ID: 29633257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-profit Drug Research and Development at a Crossroads.
    Jarosławski S; Toumi M; Auquier P; Dussart C
    Pharm Res; 2018 Feb; 35(3):52. PubMed ID: 29417233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The stock market is a source of information on the efficacy and side effects of drugs.
    Sénard JM
    Methods Find Exp Clin Pharmacol; 1996; 18 Suppl B():59-60. PubMed ID: 8899695
    [No Abstract]   [Full Text] [Related]  

  • 31. Drug-Pricing Debate Redux - Should Cost-Effectiveness Analysis Be Used Now to Price Pharmaceuticals?
    Neumann PJ; Cohen JT; Ollendorf DA
    N Engl J Med; 2021 Nov; 385(21):1923-1924. PubMed ID: 34767318
    [No Abstract]   [Full Text] [Related]  

  • 32. Pfizer to make palbociclib temporarily free on NHS.
    Burki TK
    Lancet Oncol; 2017 Jun; 18(6):e309. PubMed ID: 28506556
    [No Abstract]   [Full Text] [Related]  

  • 33. [Histomorphological findings in the rat lung following inhalation of large doses of polyvinylpyridine-N-oxide].
    Luckhaus G
    Arzneimittelforschung; 1973 Jul; 23(7):969-71. PubMed ID: 4800455
    [No Abstract]   [Full Text] [Related]  

  • 34. [Developability assessment].
    Dumas J; Huille S; Prades C
    Med Sci (Paris); 2019 Dec; 35(12):1163-1170. PubMed ID: 31903932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The costs of coronavirus vaccines and their pricing.
    Light DW; Lexchin J
    J R Soc Med; 2021 Nov; 114(11):502-504. PubMed ID: 34732097
    [No Abstract]   [Full Text] [Related]  

  • 36. Pricing of pharmaceuticals is becoming a major challenge for health systems.
    Morgan SG; Bathula HS; Moon S
    BMJ; 2020 Jan; 368():l4627. PubMed ID: 31932289
    [No Abstract]   [Full Text] [Related]  

  • 37. Can affordability and innovation coexist for medicines?
    Colbert A; Rintoul A; Simão M; Hill S; Swaminathan S
    BMJ; 2020 Jan; 368():l7058. PubMed ID: 31932276
    [No Abstract]   [Full Text] [Related]  

  • 38. Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D.
    Farid SS; Baron M; Stamatis C; Nie W; Coffman J
    MAbs; 2020; 12(1):1754999. PubMed ID: 32449439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reference-based refinements.
    Graham J
    CMAJ; 2003 Apr; 168(9):1114-5; author reply 1115. PubMed ID: 12719311
    [No Abstract]   [Full Text] [Related]  

  • 40. [Developability assessment with case studies highlighting the decision taking].
    Dumas J; Sévérac A; Lemoine C; Huille S; Rak A; Prades C
    Med Sci (Paris); 2019 Dec; 35(12):1171-1174. PubMed ID: 31903933
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.